Spero Therapeutics Inc (SPRO) Stock Analysis
Verdict: HOLD
Solid 38-month cash runway buffers pipeline execution, but predominant analyst sell/hold ratings and negative forward EPS dictate caution.
Investment score: 43/100
Analysis as of
Is Spero Therapeutics Inc stock worth reviewing? AI model thesis
The model score of 43/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 55/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 35/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Spero Therapeutics Inc opportunities and risks
What speaks for SPRO
- Substantial Cash Runway Backstop
What speaks against SPRO
- Binary Clinical and Regulatory Trial Failure Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| SPRO | 8.0x | 1.5x | 2.1x | 100.0% | 17.2% | 30.2% |
| KLRS | n/a | 0.0x | n/a | 0.0% | 0.0% | -64.7% |
| XBIT | n/a | 0.0x | 1.0x | 0.0% | 0.0% | -62.0% |
| TENX | n/a | 0.0x | 1.1x | 0.0% | 0.0% | -95.8% |
| RNTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -87.1% |
| APLM | n/a | 5.8x | n/a | 100.0% | -128.7% | -21.0% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -64.7% |
Frequently asked questions about Spero Therapeutics Inc (SPRO)
Is SPRO stock a good investment?
The cached TradeMates AI model rates Spero Therapeutics Inc as HOLD with an investment score of 43/100. The model score of 43/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is SPRO stock a buy?
The TradeMates model verdict for SPRO is HOLD with an investment score of 43/100. Treat this as a model signal to review, not a personal buy recommendation.